The first signs of diabetic neuropathy typically result from small-diameter nerve fiber dysfunction. This review synthesized the evidence for small-diameter nerve fiber neuropathy measured via quantitative sensory testing (QST) in patients with diabetes with and without painful and non-painful neuropathies. Electronic databases were searched to identify studies in patients with diabetes with at least one QST measure reflecting small-diameter nerve fiber function (thermal or electrical pain detection threshold, contact heat-evoked potentials, temporal summation or conditioned pain modulation). Four groups were compared: patients with diabetes (1) without neuropathy, (2) with non-painful diabetic neuropathy, (3) with painful diabetic neuropathy and (4) healthy individuals. Recommended methods were used for article identification, selection, risk of bias assessment, data extraction and analysis. For the meta-analyses, data were pooled using random-effect models. Twenty-seven studies with 2422 participants met selection criteria; 18 studies were included in the meta-analysis. Patients with diabetes without symptoms of neuropathy already showed loss of nerve function for heat (standardized mean difference (SMD): 0.52, p<0.001), cold (SMD: −0.71, p=0.01) and electrical pain thresholds (SMD: 1.26, p=0.01). Patients with non-painful neuropathy had greater loss of function in heat pain threshold (SMD: 0.75, p=0.01) and electrical stimuli (SMD: 0.55, p=0.03) compared with patients with diabetes without neuropathy. Patients with painful diabetic neuropathy exhibited a greater loss of function in heat pain threshold (SMD: 0.55, p=0.005) compared with patients with non-painful diabetic neuropathy. Small-diameter nerve fiber function deteriorates progressively in patients with diabetes. Because the dysfunction is already present before symptoms occur, early detection is possible, which may assist in prevention and effective management of diabetic neuropathy.
- diabetes complications
- diabetic neuropathies
- chronic pain
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
Diabetes affects 8.5% of the total adult population.1 Elevated sugar levels over time can produce tissue damage at different levels to the nervous system. Among the various forms of diabetic neuropathy, distal symmetrical polyneuropathy (DSPN) is the most common long-term diabetic complication, affecting up to 50% of patients with diabetes.2 Of those with DSPN, 13% report pain associated with the DSPN,3 which impacts on their daily activities and quality of life. DSPN is defined as a bilateral, length-dependent sensorimotor neuropathy.4 Typically, symptoms of DSPN are initially localized at the toes, before progressively affecting the feet and lower legs. DSPN in the hands is less common, and generally manifests itself after DSPN has developed in the lower limbs. Other forms of diabetic neuropathy may coexist, like cardiovascular autonomic neuropathy or atypical forms of diabetic neuropathy (eg, carpal tunnel syndrome).5
DSPN affects multiple nerves and various nerve fiber types.4 Sensory nerve fibers are typically affected before motor nerve fibers.6 In the early stages, small-diameter sensory nerve fibers responsible for thermal, electrical and pain perception (ie, Aδ and C-fibers) are affected.7 As DSPN progresses, large-diameter sensory nerve fibers responsible for touch and vibration perception (ie, Aβ and Aγ fibers) are affected.8 This may manifest itself clinically as either loss of nerve function resulting in hypoalgesia (small-diameter nerve fibers) or hypoesthesia (large-diameter nerve fibers) or gain of function, resulting in pain (small-diameter nerve fibers) or paraesthesia (large-diameter nerve fibers). Motor neuropathy (Aα fibers) may result in muscle weakness and may contribute to muscle cramps.8
Small fiber neuropathy can manifest as spontaneous and stimulus-evoked distal pain, deep aching and sensory loss.9 Patients with small fiber neuropathy are at increased risk for foot ulcerations and amputations.10 In the last 10–15 years, there is a growing interest in small fiber neuropathy in various pathologies, such as carpal tunnel syndrome11 and complex regional pain syndrome.12 Similarly, various methods have been employed to assess small-diameter nerve pathology in diabetes.6 Available techniques include skin biopsy and corneal confocal microscopy to assess morphological changes. To evaluate function, quantitative sensory testing (QST), laser-evoked potentials and sudomotor function can be assessed. Static QST measures are used to quantify gain and/or loss of somatosensory function in small-diameter and large-diameter nerve fibers. Dynamic QST measures are used to gain insights in altered pain processing in the central nervous system, such as facilitation (eg, temporal and spatial summations) and inhibition (eg, conditioned pain modulation).
As DSPN significantly increases the morbidity of diabetes,13 early detection and management of small fiber neuropathy is of cardinal importance. Multiple studies have used QST to document small fiber neuropathies in patients with diabetes with and without DSPN (eg, see Raputova et al14–19). As findings from individual studies are sometimes conflicting and unable to provide a comprehensive insight, a systematic review and meta-analysis is required. Therefore, the aim of this study was to review and summarize the evidence on altered pain thresholds and pain modulation in patients with diabetes without and with DSPN (both painful and non-painful).
Research design and methods
This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.20 The review has been registered in PROSPERO (CRD42018088173) and the protocol is available online.21
Studies were considered for inclusion in this review if they met the following criteria: (1) cohort studies, case–control studies or clinical trials conducted in adults (ie, at least 18 years of age), diagnosed with diabetes (type 1 or 2), without or with DSPN (painful or non-painful), with or without a healthy pain-free control group; (2) the study included at least one outcome related to detecting pain thresholds and/or pain modulation; and (3) the study included at least one of the following comparisons: patients with diabetes without DSPN versus patients with non-painful DSPN; patients with non-painful DSPN versus patients with painful DSPN; or patients with diabetes with or without DSPN versus healthy controls.
Pain thresholds for the sensory modalities of interest (ie, heat, cold, pressure, pain by means of electrical stimulation and contact heat-evoked potentials) and pain modulation measures (ie, temporal summation or conditioned pain modulation) were extracted. Only quantitative outcomes were considered. If different body locations where measured within the same study (eg, great toe and arch of the foot), the location most commonly used among all the studies was selected.
Data sources and searches
Combinations of controlled vocabulary, Medical Subject Headings (MeSH) and free-text terms were developed in collaboration with a university health liaison librarian. MEDLINE (via EBSCO), CINAHL (via EBSCO), Embase (via Elsevier), the Cochrane Library, SPORTDiscus, Web of Science and PEDro were searched from their respective inception dates to 16th March 2019. Reference lists from the included papers were screened for additional potentially eligible studies. Studies published in a peer-reviewed journal in any language or any type of publication status were considered. An example of the search string can be found in the protocol paper.21
Records were imported to Covidence (Veritas Health Innovation, Australia)22 for screening. One investigator (ES-S) screened titles and abstracts, and two independent investigators (ES-S and MS) screened full-text records. When there was disagreement, the two investigators discussed the eligibility, and if the disagreement could not be resolved, a third investigator (LB) was consulted. Unweighted Cohen’s kappa (κ) coefficient was calculated to quantify the agreement in full-text selection between the reviewers. Agreement was scored as fair (0.40–0.59), good (0.60–0.74) or excellent (>0.75).23
Data collection process
The data were extracted by one investigator (ES-S). The accuracy of the data extraction was verified by a second investigator (MS) who independently extracted data from a randomly selected subset of papers (20% of the total). The level of agreement for extracted mean, SD and sample size was calculated using a two-way random single measure intraclass correlation coefficient (ICC2,1). Data were extracted from each paper for (1) manuscript information (author and year); (2) study design; (3) patient information (sample size, age, sex, body mass index, type of diabetes, years since diabetes diagnosis, presence and type of neuropathy, disability and quality of life; (4) pain thresholds (cold pain threshold, heat pain threshold, pressure pain threshold, pain threshold by means of electrical stimuation and contact heat-evoked potentials); and (5) pain modulation variables (temporal summation and conditioned pain modulation).
Risk of bias in individual studies
Two investigators (ES-S and MS) analyzed the risk of bias in each paper using the Downs and Black checklist.24 This checklist was developed for healthcare interventions to assess the methodological quality of randomized controlled trials and non-randomized studies. It assesses 27 items categorized into (1) reporting, (2) external validity, (3) internal validity—bias, (4) internal validity—confounding (selection bias), and (5) power. For the purpose of this systematic review, items 5, 9–12, 14, 17, 19, 23, 24, 26 and 27 were not considered as they address aspects related to longitudinal or interventional studies. The maximum final score of the abbreviated checklist was therefore 14. Discrepancies in quality rating between the investigators were resolved by discussion, and when necessary, a third investigator (LB) was consulted. Reliability for risk of bias was assessed using an ICC2,1 with 95% CIs.
Synthesis of results
A quantitative synthesis (meta-analysis) was performed when possible. The results were pooled using a random-effect meta-analysis when appropriate. The summary statistic calculated for each study was the standardized mean difference (SMD) with 95% CI for each outcome of interest. When outcomes were reported in subgroups (eg, for diabetes type 1 and type 2), data were combined by calculating the weighted average.
Heterogeneity between studies was analyzed using I2 statistic. I2 values were interpreted according to the cut-off points of 25% (low heterogeneity), 50% (moderate heterogeneity) and 75% (high heterogeneity).23
Metaregression analysis was planned to examine whether group differences were influenced by risk of bias measured with the Downs and Black checklist. Studies with a score of <7 were considered to have low risk of bias, and studies with a score of ≥7 were considered to have high risk of bias. A metaregression was only considered when at least 10 studies were available for analysis.23
Meta-analytical comparison of the different pain threshold between the subgroups of patients was performed using the ’metafor’ package from the R-project V.2.0.0 (www.metafor-project.org).25 If a quantitative synthesis was not possible due to a lack of available data or authors failing to respond when additional information was required, a narrative synthesis was performed instead.
Initial searches yielded 3841 unique records. After screening titles and abstracts and 359 full texts were reviewed, 27 papers were included in the qualitative synthesis and 18 in the meta-analysis (online supplementary figure 1). Agreement between the two raters regarding the study selection was excellent, with a Cohen κ of 0.86 (p<0.001, 95% CI 0.58 to 1.14). Agreement on data extraction was excellent for all measures (ICC2,1≥0.95, 95% CI 0.88 to 0.99).
The included studies were published between 1987 and 16 March 2019, with 60% of the papers published in the past 10 years. Eight studies were cohort studies14 26–32 and 19 studies were cross-sectional studies.16–19 33–47 Seven studies14 31 37 38 41–43 included a group of patients with painful DSPN (n=384); 23 studies14 16–19 26–35 39–41 43–47 included a group of patients with non-painful DSPN (n=754); 13 studies18 19 29 30 33–37 44–47 included a group of patients with diabetes without DSPN (n=635); and 24 studies16–19 26–28 30–46 included a group of healthy individuals (n=615). Nine studies included only participants with type 2 diabetes17–19 34 36 37 41 42 44; 11 included both participants with type 1 and type 2 diabetes14 16 26–28 30–32 39 41 43; and 7 studies did not report the type of diabetes.29 33 35 38 45–47 Based on the studies that reported the type of diabetes, 17.6% were patients with type 1 diabetes. The participants from one study40 were not included due to a mismatch between the data reported in the text compared with the tables, and we were unable to receive clarification from the authors which data were correct.
The mean age, sex (% women) and mean duration of diabetes for the different groups were painful DSPN: 57.8 (SD 10.9) years, 39.8% women, 18.1 (SD 8.9) years; non-painful DSPN: 58.4 (SD 10.7) years, 34.5% women, 17.9 (SD 0.3) years; diabetes without DSPN: 49.7 (SD 9.2) years, 56.2% women, 9.4 (SD 4.8) years; and healthy: 48.1 (SD 12.2) years, 53.0% women. Three studies17 32 46 reported results on health-related quality of life using an adapted version of the Neurological Symptoms Score,48 or the 36-Item Short Form Health Survey (SF-36). Patients with DSPN showed a lower health-related quality of life compared with patients with diabetes without DSPN and compared with healthy participants.
The criteria to diagnose diabetic neuropathy differed between studies. Eight studies14 17 28 30 31 42 43 46 used confirmatory tests for neuropathy,6 such as intraepidermal nerve fiber density14 31 42 or electrodiagnostic tests.14 17 28 30 31 43 46 Five studies included patients with possible or probable DSPN based on questionnaires such as the Leeds Assessment of Neuropathic Symptoms and Signs,19 the Toronto Clinical Scoring system,18 the Michigan Neuropathy Screening Index,34 or the American Diabetes Association criteria.29 32 Other tests used were based on perception thresholds (eg, tuning fork), a combination of perception thresholds,16 26 27 38 41 or bedside neurological examination (eg, ankle reflexes and expert criteria)33 35 39 45 (online supplementary table 1).
The pain detection thresholds measured were heat pain threshold (17 studies),14 18 19 28–31 36 37 39–41 43–47 cold pain threshold (9 studies),14 19 29 31 36 37 40 46 47 pressure pain threshold (5 studies),14 16 26 27 31 contact heat-evoked potentials (3 studies),17 35 42 and pain threshold by means of electrical stimulation (2 studies).33 34 Two studies reported temporal summation32 38 and one study38 measured conditioned pain modulation (online supplementary table 1).
Risk of bias within studies
The mean Downs and Black score across studies was 9, ranging from 6 to 11. The item least frequently listed related to reporting adverse events. Many studies failed to provide information about the recruitment of participants (period of time or whether all participants were recruited from the same population) or blinding of the measurements (online supplementary table 2). Agreement between the two raters for the Downs and Black scores was excellent, with a Cohen κ of 0.82 (p<0.001, 95% CI 0.71 to 0.93).
Synthesis of results
Heat pain threshold
Pooled data from seven studies18 19 36 37 44–46 showed that patients with diabetes without DSPN (n=438) had increased heat pain threshold (ie, pain at higher temperatures) compared with healthy individuals (n=269) (SMD: 0.52, 95% CI 0.30 to 0.74; Z=4.71, p<0.001). The results from one study45 were presented separately for men and women, so we combined them into a single group prior to further evaluation. Four studies18 19 29 46 with low heterogeneity (I2=0%) demonstrated that patients with non-painful DSPN (n=164) had increased heat pain threshold compared with patients with diabetes without DSPN (n=275) (SMD: 0.75, 95% CI 0.55 to 0.96; Z=7.28, p<0.001; figure 1). Two studies14 31 of low heterogeneity (I2=0%) revealed that patients with painful DSPN (n=269) had a decreased heat pain threshold (ie, detect pain at lower temperatures) compared with non-painful DSPN (n=154) (SMD: 0.32, 95% CI 0.12 to 0.52; Z=−3.11, p=0.002) (figure 1). Three studies18 19 46 with moderate heterogeneity (I2=60%) revealed that patients with non-painful DSPN (n=40) presented with increased heat pain threshold compared with healthy controls (n=81) (SMD 1.02, 95% CI 0.28 to 1.78; Z=2.63, p=0.01) (online supplementary figure 2). The findings of one study41 could not be pooled because the reported values could not be converted to degrees. This study showed higher values for heat pain onset in patients with non-painful DSPN versus painful DSPN. This difference was significant in the comparison between patients with non-painful DSPN and healthy individuals. No difference was observed between patients with painful DSPN and healthy individuals.
Cold pain threshold
Four studies19 36 37 46 with high heterogeneity (I2=76%) demonstrated that patients with diabetes without DSPN (n=118) had increased cold threshold (ie, pain at lower temperatures) compared with healthy individuals (n=165) (SMD: −0.71, 95% CI -1.25 to 0.17; Z=−2.59, p=0.01). Two studies14 31 demonstrated no differences in cold pain threshold between patients with painful DSPN (n=269) and patients with non-painful DSPN (n=154) (SMD: −0.19, 95% CI −0.76 to 0.39; Z=−0.64, p=0.52). Three studies19 29 46 with moderate heterogeneity (I2=59%) showed that patients with non-painful DSPN (n=159) had increased cold threshold compared with patients with diabetes without DSPN (n=252) (SMD: −0.76, 95% CI -1.20 to 0.33; Z=−3.45, p<0.001) (figure 2).
Pressure pain threshold
Two studies14 31 with low heterogeneity (I2=8%) that compared patients with painful DSPN (n=269) and patients with non-painful DSPN (n=144) showed no difference in pressure pain threshold between groups (SMD 0.14, 95% CI −0.07 to 0.36; Z=1.33, p=0.18) (figure 3). Three studies16 26 27 with moderate heterogeneity (I2=73%) revealed no differences in pressure pain threshold between patients with non-painful DSPN (n=42) and healthy participants (n=70) (SMD 0.60, 95% CI –0.20 to 1.40; Z=1.46, p=0.14) (online supplementary figure 3). Findings from one study32 could not be pooled because the authors used a cut-off point (seven on a Visual Analogue Scale) rather than the amount of pressure that coincided with the first experience of painful pressure.
Pain threshold by means of electrical stimulation
Two studies33 34 with high heterogeneity (I2=80%) showed that patients with diabetes without DSPN (n=70) had an increased pain threshold by means of electrical threshold (ie, pain at higher intensity) compared with healthy participants (n=50) (SMD: 1.26; 95% CI: 0.27, 2.25; Z=2.49, p=0.01) (figure 4). The same studies33 34 revealed an increased threshold in patients with non-painful DSPN (n=29) compared with patients with diabetes without DSPN (n=70) (SMD: 0.55; 95% CI: 0.05, 1.05; Z=2.15, p=0.03). Heterogeneity was low for this comparison (I2=13%). These studies33 34 with low heterogeneity (I2=0%) revealed that patients with non-painful DSPN (n=29) had an increased threshold compared with healthy individuals (n=50) (SMD: 1.85, 95% CI 1.30 to 2.39; Z=6.63, p<0.001) (online supplementary figure 4).
Contact heat-evoked potentials
Two studies17 35 with high heterogeneity (I2=78%) demonstrated no differences in contact heat-evoked potentials between patients with non-painful DSPN (n=36) and healthy individuals (n=42) (SMD: −0.55, 95% CI −1.81 to 0.70; Z=−0.87, p=0.39) (online supplementary figure 5).
Pain modulation mechanisms could not be pooled. One study38 showed that patients with a longer duration (>2 years) of painful DSPN (n=20) had more efficient conditioned pain modulation compared with patients with shorter duration (≤2 years) of painful DSPN (n=13) and compared with healthy individuals (n=29). Moreover, a less pronounced temporal summation was observed in patients with longer painful DSPN duration compared with shorter painful DSPN duration. No differences were shown in any pain modulation variable between patients with longer painful DSPN duration and healthy individuals. Another study32 reported no differences in temporal summation between patients with non-painful DSPN and healthy individuals.
Due to the small number of studies included in the meta-analyses (<10 studies per outcome), we could not perform a meta-regression analysis.49
This systematic review and meta-analysis revealed four important findings: (1) patients with diabetes without symptoms of DSPN already show loss of function of small-diameter nerve fibers; (2) loss of small-diameter nerve fiber function is progressive across the diabetes groups (diabetes without DSPN vs diabetes with non-painful DSPN; diabetes with non-painful DSPN vs diabetes with painful DSPN); (3) there is no overall gain of function of small-dimeter nerve fibers in patients with painful DSPN; and (4) central nervous system pain modulation mechanisms are understudied in diabetes with or without DSPN.
This review demonstrated that loss of small-diameter nerve fiber function already occurs in patients with diabetes without symptoms of DSPN. In clinical settings, DSPN is typically diagnosed based on patient-reported symptoms. Therefore, early signs of DSPN may be overlooked unless a specific evaluation of the somatosensory pathways is performed. Routine electrodiagnostic test methods (conduction velocity) are insufficient as they assess predominantly large-diameter nerve fiber function. If increased sensory thresholds indicate a preclinical state of DSPN, QST or bedside neurological testing, including small-diameter nerve fiber function, could potentially be a valuable non-invasive tool to assist in early diagnosis, and possibly prevention and management of DSPN. Furthermore, the fact that small-diameter nerve fiber neuropathy is already establishing before symptoms of DSPN become apparent may be an important realization for people with diabetes. It may be a convincing educational message for patients with diabetes to adhere to healthy lifestyle guidelines.50 C-fibers play a crucial role in tissue healing, and dysfunction in these unmyelinated small-diameter nerve fibers may increase the morbidity of cutaneous and subcutaneous conditions due to the delayed healing, and risk of infections, even in people with diabetes without symptoms of DSPN.51
The greater loss of small-diameter nerve fiber function for patients with non-painful DSPN compared with patients without symptoms of DSPN is in line with expectations. Loss of small-diameter nerve fiber function is commonly observed in other polyneuropathies, such as in people with HIV-associated peripheral neuropathy52 or Guillain-Barre syndrome.53
For painful neuropathies, hyperalgesia and allodynia are typically associated with gain of small-diameter nerve fiber function and/or altered postsynaptic processing in spinal and supra-spinal neurons.54 People with mononeuropathies (eg, radiculopathy55) and polyneuropathies (eg, chemotherapy-induced neuropathy56) show a gain of small-diameter nerve fiber function for various QST modalities. The observed greater loss of small-diameter nerve function in people with painful DSPN compared with people with non-painful DSPN is therefore paradoxical. Painful DSPN cannot be explained by static QST measures.
Other methods, such as corneal confocal microscopy57 and MRI,58 have identified differences between people with painful DSPN and non-painful DSPN. Imaging studies using MRI have shown that people with painful DSPN characterized by loss of function have a reduction in spinal cord and primary somatosensory cortical grey matter volume compared with patients with non-painful DSPN.58 Furthermore, patients with painful-DSPN appear to have greater thalamic vascularity at rest with increased relative cerebral blood flow compared with patients with no DSPN and painless DSPN.59 It has been suggested that different processing of nociceptive signals occurs in the central nervous system’s pain modulatory system, resulting in reduced inhibition and increased amplification in patients with painful DSPN.60 This can be evaluated with dynamic QST measures (such as conditioned pain modulation and temporal and special summation). Unfortunately, our review revealed that these measures are understudied in diabetes.
An important consideration is that in the original studies, and therefore also in the current review and meta-analysis, the results are reported as either loss or gain of nerve function at group level. Rather than analyzing QST modalities separately, there is a recent evolution to various group QST modalities together to create sensory phenotypes. Large phenotyping studies14 31 61 revealed that although loss of nerve function is the most prevalent phenotype (64%) in patients with painful DSPN, a substantial portion of patients have a gain of function phenotype (thermal hyperalgesia: 13%, mechanical hyperalgesia: 19% (4% had a profile similarly to healthy participants)).61 The phenotype loss of function and the phenotype gain of function are also both present in other neuropathies, such as postherpetic neuralgia.62This illustrates that although we did observe loss of nerve function at group level (diabetes without symptoms of DSPN, patients with non-painful DSPN and patients with painful DSPN), individual assessment of small-diameter nerve fiber function remains important.
A limitation of the review is that most comparisons showed moderate or high heterogeneity. It is important to note that most of the studies included a mix of patients with type 1 and type 2 diabetes. Although the mechanisms underlying diabetic neuropathy remain not fully understood,63 it is apparent that different mechanisms are present in diabetic neuropathy in patients with type 1 and type 2 diabetes.64 65 The source of heterogeneity between studies could be influenced by differences in sample size, sampling methods, and population characteristics, including the composition of the sample (type 1 and/or type 2 diabetes), diversity of QST protocols66 and criteria to diagnose DSPN. The lack of reporting population characteristics and small sample sizes may also influence heterogeneity, as pain thresholds are known to vary by sex67 or age.68 Furthermore, consistent with a previous systematic review on QST,66 we found large variability in the reporting of QST protocols. We recommend that researchers and clinicians adhere to published guidelines on the use and reporting of QST69 and to report the results for patients with type 1 and type 2 diabetes separately.
Contributors ES-S, MWC and LB developed the idea for the review. ES-S developed the search strategy, selection criteria and data extraction form, with guidance from MWC and LB. ES-S and MS performed the literature searches, screened the literature, extracted the data and appraised the quality of the included papers. LB acted as third reviewer when necessary. ES-S developed the meta-analysis plan and designed the figures and tables. ES-S and MWC wrote the manuscript, with input from LB. All authors read and approved the final version of the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval This systematic review and meta-analysis was based on published data. As researchers did not access any information that could lead to the identification of an individual patient, no concerning ethical issue was raised in this research. Therefore, obtaining ethical approval and consent of participants was waived.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available upon reasonable request. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.